@article {7047,
	title = {A systematic literature review and network meta-analysis of treatments for patients with untreated multiple myeloma not eligible for stem cell transplantation},
	journal = {Leukemia and Lymphoma},
	volume = {58},
	year = {2017},
	note = {Export Date: 18 February 2017References: McCarthy, P.L., Palumbo, A., Maintenance therapy for multiple myeloma (2014) Hematol Oncol Clin North Am, 28, pp. 839-859;Faiman, B., Richards, T., Innovative agents in multiple myeloma (2014) J Adv Pract Oncol, 5, pp. 193-202; 
Engelhardt, M., Terpos, E., Kleber, M., European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma (2014) Haematologica, 99, pp. 232-242; 
Moreau, P., Rajkumar, S.V., Should all eligible patients with multiple myeloma receive autologous stem-cell transplant as part of initial treatment? (2012) Leuk Res, 36, pp. 677-681; 
Benboubker, L., Dimopoulos, M.A., Dispenzieri, A., Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma (2014) N Engl J Med, 371, pp. 906-917; 
Ades, A.E., A chain of evidence with mixed comparisons: models for multi-parameter synthesis and consistency of evidence (2003) Stat Med, 22, pp. 2995-3016; 
Caldwell, D.M., Ades, A.E., Higgins, J.P., Simultaneous comparison of multiple treatments: combining direct and indirect evidence (2005) Bmj, 331, pp. 897-900; 
Lu, G., Ades, A.E., Combination of direct and indirect evidence in mixed treatment comparisons (2004) Stat Med, 23, pp. 3105-3124; 
Liberati, A., Altman, D.G., Tetzlaff, J., The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration (2009) BMJ, 339, p. b2700; 
Tierney, J.F., Stewart, L.A., Ghersi, D., Practical methods for incorporating summary time-to-event data into meta-analysis (2007) Trials, 8, p. 16; 
Higgins, J.P., Altman, D.G., Gotzsche, P.C., The Cochrane Collaboration{\textquoteright}s tool for assessing risk of bias in randomised trials (2011) BMJ, 343, p. d5928; 
Dias, S., Sutton, A.J., Ades, A.E., Evidence synthesis for decision making 2: a generalized linear modeling framework for pairwise and network meta-analysis of randomized controlled trials (2013) Med Decis Making, 33, pp. 607-617; 
Facon, T., Mary, J.Y., Hulin, C., Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial (2007) Lancet, 370, pp. 1209-1218; 
Hulin, C., Facon, T., Rodon, P., Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 trial (2009) J Clin Oncol, 27, pp. 3664-3670; 
Sacchi, S., Marcheselli, R., Lazzaro, A., A randomized trial with melphalan and prednisone versus melphalan and prednisone plus thalidomide in newly diagnosed multiple myeloma patients not eligible for autologous stem cell transplant (2011) Leuk Lymphoma, 52, pp. 1942-1948; 
Brooks, S.P., Gelman, A., Alternative methods for monitoring convergence of iterative simulations (1998) J Comput Graph Stat, 7, pp. 434-455; 
Gelman, A., Inference and monitoring convergence (1996) Markov chain Monte Carlo in practice, pp. 1143-1311. , Gilks W.R., Richardson S., Spiegelhalter D.J., (eds), London: Chapman \& Hall; 
Facon, T., Dimopoulos, M.A., Hulin, C., (2015)Beksac, M., Haznedar, R., Firatli-Tuglular, T., Addition of thalidomide to oral melphalan/prednisone in patients with multiple myeloma not eligible for transplantation: results of a randomized trial from the Turkish Myeloma Study Group (2011) Eur J Haematol, 86, pp. 16-22; 
Facon, T., Mary, J.Y., Pegourie, B., Dexamethasone-based regimens versus melphalan-prednisone for elderly multiple myeloma patients ineligible for high-dose therapy (2006) Blood, 107, pp. 1292-1298; 
Mateos, M.V., Oriol, A., Martinez-Lopez, J., Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial (2010) Lancet Oncol, 11, pp. 934-941; 
Morgan, G.J., Davies, F.E., Gregory, W.M., Cyclophosphamide, thalidomide, and dexamethasone (CTD) as initial therapy for patients with multiple myeloma unsuitable for autologous transplantation (2011) Blood, 118, pp. 1231-1238; 
Palumbo, A., Bringhen, S., Liberati, A.M., Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial (2008) Blood, 112, pp. 3107-3114; 
Palumbo, A., Bringhen, S., Rossi, D., Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial (2010) J Clin Oncol, 28, pp. 5101-5109; 
Palumbo, A., Hajek, R., Delforge, M., Continuous lenalidomide treatment for newly diagnosed multiple myeloma (2012) N Engl J Med, 366, pp. 1759-1769; 
Magarotto, V., Bringhen, S., Offidani, M., Triplet vs doublet lenalidomide-containing regimens for the treatment of elderly patients with newly diagnosed multiple myeloma (2016) Blood, 127, pp. 1102-1108; 
San Miguel, J.F., Schlag, R., Khuageva, N.K., Persistent overall survival benefit and no increased risk of second malignancies with bortezomib-melphalan-prednisone versus melphalan-prednisone in patients with previously untreated multiple myeloma (2013) J Clin Oncol, 31, pp. 448-455; 
San-Miguel, J., Blade, J., Shpilberg, O., Phase 2 randomized study of bortezomib-melphalan-prednisone with or without siltuximab (anti-IL-6) in multiple myeloma (2014) Blood, 123, pp. 4136-4142; 
Waage, A., Gimsing, P., Fayers, P., Melphalan and prednisone plus thalidomide or placebo in elderly patients with multiple myeloma (2010) Blood, 116, pp. 1405-1412; 
Wijermans, P., Schaafsma, M., Termorshuizen, F., Phase III study of the value of thalidomide added to melphalan plus prednisone in elderly patients with newly diagnosed multiple myeloma: the HOVON 49 Study (2010) J Clin Oncol, 28, pp. 3160-3166; 
Stewart, A.K., Jacobus, S., Fonseca, R., (2014)Palumbo, A., Bringhen, S., Caravita, T., Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial (2006) Lancet, 367, pp. 825-831; 
San Miguel, J.F., Schlag, R., Khuageva, N.K., Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma (2008) N Engl J Med, 359, pp. 906-917; 
Fayers, P.M., Palumbo, A., Hulin, C., Thalidomide for previously untreated elderly patients with multiple myeloma: meta-analysis of 1685 individual patient data from 6 randomized clinical trials (2011) Blood, 118, pp. 1239-1247; 
Palumbo, A., Waage, A., Hulin, C., Safety of thalidomide in newly diagnosed elderly myeloma patients: a meta-analysis of data from individual patients in six randomized trials (2013) Haematologica, 98, pp. 87-94; 
Zou, Y., Sheng, Z., Niu, S., Lenalidomide versus thalidomide based regimens as first-line therapy for patients with multiple myeloma (2013) Leuk Lymphoma, 54, pp. 2219-2225; 
Morabito, F., Bringhen, S., Larocca, A., Bortezomib, melphalan, prednisone (VMP) versus melphalan, prednisone, thalidomide (MPT) in elderly newly diagnosed multiple myeloma patients: A retrospective case-matched study (2014) Am J Hematol, 89, pp. 355-362; 
Kumar, A., Hozo, I., Wheatley, K., Thalidomide versus bortezomib based regimens as first-line therapy for patients with multiple myeloma: a systematic review (2011) Am J Hematol, 86, pp. 18-24; 
http://www.nice.org.uk/guidance/ta228Delforge, M., Minuk, L., Eisenmann, J.C., Health-related quality-of-life in patients with newly diagnosed multiple myeloma in the FIRST trial: lenalidomide plus low-dose dexamethasone versus melphalan, prednisone, thalidomide (2015) Haematologica, 100, pp. 826-833
},
	month = {2017},
	pages = {153 - 161},
	abstract = {In newly diagnosed multiple myeloma (MM), patients ineligible for front-line autologous stem cell transplantation (ASCT), melphalan and prednisone (MP) with thalidomide (MPT) or bortezomib (VMP) are standard first-line therapeutic options. Despite new treatment regimens incorporating bortezomib or lenalidomide, MM remains incurable. The FIRST study demonstrated significant improvement in progression-free survival (PFS) and overall survival (OS) for the combination of lenalidomide and low-dose dexamethasone (Rd) until progression vs. MPT in transplant-ineligible ndMM patients. However, to date no head-to-head randomized controlled trials (RCTs) have compared Rd or MPT versus VMP. We conducted a network meta-analysis using RCTs identified through a systematic literature review to evaluate the relative efficacy of Rd versus other regimens on survival endpoints in previously untreated MM patients ineligible for ASCT. In this analysis, Rd was associated with a significant PFS and survival advantage versus other first-line treatments (VMP, MPT, MP), challenging the role of alkylators in this setting. {\textcopyright} 2016 The Author(s). Published by Informa UK Limited, trading as Taylor \& Francis Group.},
	keywords = {Lenalidomide, multiple myeloma, network meta-analysis, systematic review},
	url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-84973911519\&doi=10.1080\%2f10428194.2016.1177772\&partnerID=40\&md5=0d0f982e1824f8c8b4d5d20a01132129},
	author = {Weisel, K. and Doyen, C. and Dimopoulos, M. and Yee, A. and Lahuerta, J.J. and Martin, A. and Travers, K. and Druyts, E. and Toor, K. and Abildgaard, N. and Lu, J. and Van Droogenbroeck, J. and Geraldes, C. and Petrini, M. and Voillat, L. and Voog, E. and Facon, T.}
}
